Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer

Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer

Breast cancer is a public health concern and is currently the fifth cause of mortality worldwide. Identification of different biological subtypes is essential for clinical management; therefore, the role of pathologists is essential and useful tools for immunohistochemistry diagnosis are needed. Pol...

Full description

Saved in:
Bibliographic Details
Published in:Cancers Vol. 13; no. 22; p. 5616
Main Authors: Fernandez, Eugenia, Ubillos, Luis, Elgul, Nabila, Festari, María Florencia, Mazal, Daniel, Pritsch, Otto, Alonso, Isabel, Osinaga, Eduardo, Berois, Nora
Format: Journal Article
Language:English
Published: Basel MDPI AG 10-11-2021
MDPI
Subjects:
Antibodies
Binding sites
Biomarkers
Bone marrow
Breast cancer
Cancer therapies
Cell adhesion
Diagnosis
Embedding
Enzymes
Glycosylation
Immunization
Immunohistochemistry
Lung cancer
Lymph nodes
Lymphatic system
Medical prognosis
Medical research
Metastases
Metastasis
Molecular modelling
Monoclonal antibodies
Mucin
Neuroblastoma
Paraffin
Patients
Polypeptides
Polysaccharides
Proteins
Public health
Sensors
Tumor cell lines
Tumorigenesis
Tumors
United Kingdom > UK
United States > US
Sweden
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is a public health concern and is currently the fifth cause of mortality worldwide. Identification of different biological subtypes is essential for clinical management; therefore, the role of pathologists is essential and useful tools for immunohistochemistry diagnosis are needed. Polypeptide-GalNAc-transferases are emerging novel biomarkers related to cancer behavior and GalNAc-T13, correlated with aggressiveness in some tumors, is an interesting candidate. Few monoclonal antibodies reacting with native proteins, and not affected by fixation and paraffin embedding, have been reported. The aim of this work was to develop a useful monoclonal antibody anti-GalNAc-T13 and to assess its potential significance in breast cancer diagnosis. We evaluated 6 human breast cancer cell lines, 338 primary breast tumors and 48 metastatic lymph nodes and looked for clinical significance correlating GalNAc-T13 expression with patients’ clinical features and survival. We found high GalNAc-T13 expression in 43.8% of the cases and observed a significant higher expression in metastatic lymph nodes, correlating with worse overall survival. We hypothesized several possible molecular mechanisms and their implications. We conclude that GalNAc-T13 may be a novel biomarker in breast cancer, useful for routine pathological diagnosis. Elucidation of molecular mechanisms related to aggressiveness should contribute to understand the role of GalNAc-T13 in breast cancer biology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13225616